Pseudoephedrine hydrochloride

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies. It effectively reduces swelling of the nasal passages and alleviates sinus pressure.

Dosage and Administration

Adults and children aged 12 years and over are instructed to swallow one whole tablet with water once every 24 hours. It is imperative that the dosage does not exceed one tablet within a 24-hour period. The tablet must not be divided, crushed, chewed, or dissolved prior to ingestion. It is important to note that the tablet does not completely dissolve and may be observed in the stool, which is a normal occurrence.

This product is contraindicated for use in children under 12 years of age.

Contraindications

There are no explicit contraindications identified for this product. However, it is advised that patients do not exceed the recommended dosage.

In the event of nervousness, dizziness, or sleeplessness, patients should discontinue use and consult a healthcare professional. Additionally, if symptoms do not improve within 7 days, occur with a fever, or if persistent abdominal pain or vomiting is experienced, medical advice should be sought.

Warnings and Precautions

It is imperative that this product not be used concurrently with prescription monoamine oxidase inhibitors (MAOIs), which are medications prescribed for depression, psychiatric or emotional conditions, or Parkinson’s disease. Additionally, this product should not be taken for a minimum of two weeks following the discontinuation of an MAOI. Healthcare professionals should advise patients to consult with a doctor or pharmacist if there is uncertainty regarding the presence of an MAOI in their current prescription medications.

Patients are instructed to discontinue use and seek medical advice if they experience any of the following symptoms: nervousness, dizziness, or sleeplessness. Furthermore, if symptoms do not show improvement within seven days or are accompanied by a fever, or if the patient experiences persistent abdominal pain or vomiting, they should contact their healthcare provider immediately.

In the event of an overdose, it is crucial to obtain emergency medical assistance without delay. Patients or caregivers should contact a Poison Control Center at 1-800-222-1222 for immediate guidance.

Side Effects

Patients should be aware of the potential adverse reactions associated with the use of this medication. Serious adverse reactions may occur, particularly in individuals who are currently taking or have recently discontinued a prescription monoamine oxidase inhibitor (MAOI). The use of this medication is contraindicated in such cases, as it may lead to significant health risks.

Common adverse reactions reported include nervousness, dizziness, and sleeplessness. Patients are advised to discontinue use if these symptoms occur. Additionally, if symptoms do not improve within 7 days, or if they are accompanied by a fever, patients should seek medical attention. Persistent abdominal pain or vomiting is another reason to stop use and consult a healthcare provider.

Patients with pre-existing conditions should exercise caution and consult a doctor before using this medication. This includes individuals with heart disease, high blood pressure, thyroid disease, diabetes, or those experiencing trouble urinating due to an enlarged prostate gland. Furthermore, patients with a history of bowel obstruction or narrowing should be particularly vigilant, as the medication may rarely cause bowel obstruction, especially in those with severe narrowing of the bowel (esophagus, stomach, or intestine).

Monitoring for these adverse reactions is essential to ensure patient safety and effective management of any potential complications.

Drug Interactions

The use of pseudoephedrine is contraindicated in patients who are currently taking a prescription monoamine oxidase inhibitor (MAOI) or within two weeks of discontinuing an MAOI. This combination may result in serious interactions that could pose significant health risks.

No additional drug interactions or laboratory test interactions have been identified. Therefore, no further dosage adjustments or monitoring recommendations are necessary beyond the aforementioned contraindication.

Packaging & NDC

Below are the non-prescription pack sizes of Pseudoephedrine Hydrochloride. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients under 12 years of age should not use this product. For adolescents aged 12 years and older, the recommended dosage is one whole tablet swallowed with water every 24 hours, with a maximum of one tablet in a 24-hour period.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is no specific data available regarding the excretion of this medication in breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on the clinical presentation.

For further guidance, healthcare professionals should refer to established protocols and consult relevant toxicology resources.

Nonclinical Toxicology

If pregnant or breastfeeding, it is advised to consult a health professional prior to use. No specific non-teratogenic effects have been identified in the available data. Additionally, there are no detailed findings regarding nonclinical toxicology or animal pharmacology and toxicology provided in the current information.

Postmarketing Experience

Postmarketing experience has identified rare cases of bowel obstruction, typically occurring in individuals with significant narrowing of the bowel, including the esophagus, stomach, or intestine. These events were reported voluntarily or through surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 in the event of an overdose. It is important for patients to understand the seriousness of an overdose and the necessity of prompt action to ensure their safety.

Storage and Handling

The product is supplied in individual blister units. Each blister unit must remain intact; do not use if the unit is open or torn.

For optimal storage conditions, the product should be maintained at a temperature range of 20° to 25°C (68° to 77°F). Proper handling and storage are essential to ensure the integrity and efficacy of the product.

Additional Clinical Information

Patients are advised to swallow one whole tablet with water every 24 hours. For individuals aged 12 years and older, it is important not to exceed one tablet within a 24-hour period, and the tablet should not be divided, crushed, chewed, or dissolved.

Clinicians should counsel patients to consult a health professional if they are pregnant or breastfeeding. Additionally, it is crucial to keep the medication out of reach of children. In the event of an overdose, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

Drug Information (PDF)

This file contains official product information for Pseudoephedrine Hydrochloride, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)